Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul N Faust

Showing results (131-140 of 225) with videos related to

Pageof 23
Sort By:
BMJ Open|May 25, 2019
Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT)Mark D Lyttle, Julia A Bielicki, Sam Barratt, et al.
The Journal of Infection|May 19, 2026
A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus VaccineAlasdair Ps Munro, Matteo Ferrari, Rebecca Kinsley, et al.
Vaccine|August 26, 2025
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)Grace Li, Natalie G Marchevsky, Grace Macaulay, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2016
Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae BiofilmsSamuel A Collins, Michael J Kelso, Ardeshir Rineh, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 13, 2011
A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal diseasePascal Renner, Thierry Roger, Pierre-Yves Bochud, et al.
Journal of Medical Microbiology|June 22, 2018
Ecology and diversity in upper respiratory tract microbial population structures from a cross-sectional community swabbing studyAbigail L Coughtrie, Denise E Morris, Rebecca Anderson, et al.
Frontiers in Pediatrics|June 7, 2022
Multicenter Randomized Trial of Methylprednisolone vs. Intravenous Immunoglobulins to Treat the Pediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS): Protocol of the Swissped RECOVERY TrialTatjana Welzel, Nina Schöbi, Maya C André, et al.
The New England Journal of Medicine|December 29, 2023
Nirsevimab for Prevention of Hospitalizations Due to RSV in InfantsSimon B Drysdale, Katrina Cathie, Florence Flamein, et al.
The Lancet. Infectious Diseases|July 10, 2025
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSpyros Chalkias, Patrick Dennis, Dena Petersen, et al.
The Lancet. Child & Adolescent Health|May 16, 2025
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trialAlasdair P S Munro, Simon B Drysdale, Katrina Cathie, et al.
Pageof 23

Showing results (131-140 of 225) with videos related to

Sort By:
Pageof 23
BMJ Open|May 25, 2019
Efficacy, safety and impact on antimicrobial resistance of duration and dose of amoxicillin treatment for young children with Community-Acquired Pneumonia: a protocol for a randomIsed controlled Trial (CAP-IT)Mark D Lyttle, Julia A Bielicki, Sam Barratt, et al.
The Journal of Infection|May 19, 2026
A phase I, needle free, dose escalation clinical trial of pEVAC-PS, a candidate pan-Sarbecovirus VaccineAlasdair Ps Munro, Matteo Ferrari, Rebecca Kinsley, et al.
Vaccine|August 26, 2025
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)Grace Li, Natalie G Marchevsky, Grace Macaulay, et al.
Antimicrobial Agents and Chemotherapy|December 7, 2016
Cephalosporin-3'-Diazeniumdiolate NO Donor Prodrug PYRRO-C3D Enhances Azithromycin Susceptibility of Nontypeable Haemophilus influenzae BiofilmsSamuel A Collins, Michael J Kelso, Ardeshir Rineh, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 13, 2011
A functional microsatellite of the macrophage migration inhibitory factor gene associated with meningococcal diseasePascal Renner, Thierry Roger, Pierre-Yves Bochud, et al.
Journal of Medical Microbiology|June 22, 2018
Ecology and diversity in upper respiratory tract microbial population structures from a cross-sectional community swabbing studyAbigail L Coughtrie, Denise E Morris, Rebecca Anderson, et al.
Frontiers in Pediatrics|June 7, 2022
Multicenter Randomized Trial of Methylprednisolone vs. Intravenous Immunoglobulins to Treat the Pediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS): Protocol of the Swissped RECOVERY TrialTatjana Welzel, Nina Schöbi, Maya C André, et al.
The New England Journal of Medicine|December 29, 2023
Nirsevimab for Prevention of Hospitalizations Due to RSV in InfantsSimon B Drysdale, Katrina Cathie, Florence Flamein, et al.
The Lancet. Infectious Diseases|July 10, 2025
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSpyros Chalkias, Patrick Dennis, Dena Petersen, et al.
The Lancet. Child & Adolescent Health|May 16, 2025
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trialAlasdair P S Munro, Simon B Drysdale, Katrina Cathie, et al.
Pageof 23